These findings underscore the dual utility of EZH2 inhibitors: they not only suppress tumor-intrinsic proliferation but also remodel the TIME to favor immune-mediated clearance, offering a strategic advantage in immunotherapy-resistant ovarian cancer [178]. This evidence concerns the gene EZH2 and ovarian carcinoma.